Lumasiran

(Oxlumo)

Lumasiran

Drug updated on 11/15/2023

Dosage FormInjection (subcutaneous: 94.5 mg/0.5 mL)
Drug ClassHAO1-directed small interfering ribonucleic acid
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.

Product Monograph / Prescribing Information

Document TitleYearSource
Oxlumo (lumasiran) Prescribing Information.2022Alnylam Pharmaceuticals, Inc., Cambridge, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines